January 9, 2018 / 12:26 PM / 9 days ago

BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial

Jan 9 (Reuters) - Axsome Therapeutics Inc:

* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL

* AXSOME THERAPEUTICS- IN CREATE-1 TRIAL, AXS-02 TREATMENT RESULTED IN SIGNIFICANT REDUCTION OF SERUM CTX AS COMPARED TO PLACEBO

* AXSOME THERAPEUTICS- IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION IN BOTH STUDIES, CONFIRMED THAT AXS-02 WAS SAFE AND GENERALLY WELL-TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below